“…Studies were conducted between 2005–2021 and they were based in the following countries: US ( n = 10), Taiwan ( n = 5), China ( n = 5), India ( n = 3), Japan ( n = 2), Malaysia ( n = 1), Australia ( n = 1), Sri Lanka ( n = 1), New Zealand ( n = 1), Colombia ( n = 1), Hong Kong ( n = 1), Poland ( n = 1), Brazil ( n = 1), and France ( n = 1). The samples were obtained from patients with HNSCC, of which OSCC was the most frequently studied tumor [ 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 ]. The studies also included samples from the following: oropharyngeal squamous cell carcinoma (OPSCC) [ 21 , 43 ], gingival squamous cell carcinoma (GSCC) [ 44 ]; unspecified oral cavity cancer (OCC) (45); oropharyngeal cancers (OPC) [ 45 ]; nasopharyngeal carcinoma (NPC) [ 46 ]; unspecified HNSCCs [ 47 , 48 , 49 , 50 , 51 ].…”